With the wide spread of Delta mutant worldwide, the COVID-19 infection situation is worrisome. In addition to vaccination for prevention, drug therapy can alleviate the disease deterioration of patients and improve clinical benefits, which is an important part of the treatment plan for COVID-19.
Recently, the COVID-19 human immunoglobulin (pH4) for intravenous injection developed by Tiantan Biological Products Co., Ltd. has obtained the Drug Clinical Trial Approval Document issued by National Medical Products Administration, and the clinical trials were approved. COVID-19 specific immunity is a specific human immunoglobulin made from the plasma of healthy people immunized with inactivated virus vaccine, which contains highly effective neutralizing antibody against SARS-CoV-2. It is the first in the world. This is another meaningful attempt by domestic bio pharmaceutical companies aimed at the treatment of COVID-19.
With the wide spread of Delta mutant worldwide, the COVID-19 infection situation is worrisome. In addition to vaccination for prevention, drug therapy can alleviate the disease deterioration of patients and improve clinical benefits, which is an important part of the treatment plan for COVID-19.
COVID-19 drugs that have been approved for marketing/emergency use authorization in the world
Up to now, there are not many COVID-19 drugs that have been approved for marketing/emergency use authorization in the world. The drugs approved for marketing are remdesivir of Gilead, Molnupiravir of MSD, REGEN-COV2 of Regeneron/Roche Pharmaceuticals; COVID-19 drugs approved for emergency use authorization are baricitinib of Eli Lilly Pharmaceuticals, Bamlanivimab/Etesevimab of Griffin/Eli Lilly Pharmaceuticals, Sotrovimab of GSK and proxalutamide of Kintor Pharmaceuticals.
COVID-19 drugs that have been approved for marketing/emergency use authorization in the world
Source: Public data compilation
In terms of drug categories, COVID-19 drugs that have been approved for marketing/ emergency use authorization worldwide cover pharmaceutical chemicals, neutralizing antibodies and macromolecular non-neutralizing antibody drugs.
Pharmaceutical chemicals, remdesivir and Molnupiravir, are RdPR inhibitor, which can be incorporated into newly synthesized viral RNA chain to hinder the replication of viral RNA. Cocktail therapy REGEN-COV2 belongs to S protein antibody, which is aimed at two independent and non-overlapping sites of SARS-CoV-2 S protein receptor binding region, and can reduce the risk of virus mutation and escape, and prevent virus from entering cells. Baricitinib is an AAK1 and JAK inhibitor, which was originally used to treat rheumatoid arthritis. It has the potential activity of blocking SARS-CoV-2 infection and reducing inflammatory reaction by inhibiting JAK pathway. Bamlanivimab/Etesevimab is a neutralizing monoclonal antibody targeting SARS-CoV-2 S protein, which was isolated from the serum of patients in the recuperation period from China and the United States. Sotrovimab is an all-human SARS-CoV-2 monoclonal neutralizing antibody, which can bind with S protein to prevent virus from entering cells of human body. Proxalutamide is an androgen receptor (AR) antagonist, which is used in many AR-related indications. In the treatment of COVID-19, proxalutamide can reduce the gene transcription and translation of ACE2 receptor and TMPRSS2 protease, and block SARS-CoV-2 from entering host cells.
Some under-research domestic COVID-19 drugs entering the Phase III clinical stage
In addition to the above-mentioned COVID-19 drugs which have been approved for marketing/ emergency use authorization, there are currently about 400 under-research COVID-19 drugs in the clinical research stage according to incomplete statistics. Among them, many domestic under-research COVID-19 drugs have entered Phase II...
(All Rights Reserved)